| | | IMPLEMENTING BYOD ACROSS PHASE II AND III CLINICAL TRIALS | | The significant advantages for electronic patient-reported outcomes (ePRO) over paper records include improved compliance, data quality, and patient experiences – these advantages will best be realized only when Bring Your Own Device (BYOD) for the collection of patient-reported outc... | | |
| |
| |
| | | MAB INDUSTRY IN CHINA : BIOSIMILARS VS INNOVATIVE BIOLOGICS | | Following patent cliffs for Erbitux, Rituxan, Sandosta_n and several big blockbusters, Herceptin, Avastin are now among the next biosimilar targets. This is creating huge potential for biosimilars, prompting innovators to shift their focus to target more emerging markets which remain untap... | | |
| | | BIOLOGY BY DESIGN: APPLYING GIGABASES OF DNA TO BIOENGINEERING
| | For more than 15 years, the costs of DNA sequencing and synthesis have been improving faster than Moore’s Law. The impacts of the improvements made to DNA sequencing are well known: whereas the original Human Genome Project cost several billion dollars, a human genome can be sequence... | | |
| |